BeiGene
Novartis gives up on tislelizumab, BeiGeneās PD-1 inhibitor approved in Europe
Anika Sharma
Novartis has terminated its significant cancer immunotherapy collaboration with BeiGene, ending a partnership that had granted Novartis co-development and co-commercialization ...
The legacy of Bristol Myers and BeiGene Celgene’s payment comes years after China’s prohibition
SG Tylor
In 2020, an unexpected manufacturing issue led to a ban on the import of Bristol Myers Squibb’s (BMS) Abraxane, distributed ...
Teva’s CEO Francis Recruits Angus Grant, Former BeiGene Business Development Head
SG Tylor
Teva Pharmaceutical Industries Ltd., the worldās largest maker of generic drugs, has announced the appointment of a new executive to ...
Zanubrutinib Plus Obinutuzumab for R/R Follicular Lymphoma Receives FDA Acceptance of sNDA
SG Tylor
Source – BeiGene BeiGene has announced that the FDA has accepted a supplemental new drug application (sNDA) for the combination ...
In a heated dispute over blood cancer treatment, AbbVie sues BeiGene over a brand-new Imbruvica patent
SG Tylor
AbbVie’s Pharmacyclics division claims that BeiGene’s Bruki Nsa violates a patent on its blood cancer medication Imbruvica in a recent ...
